Please login to the form below

How pembrolizumab will change the management of advanced lung cancer

The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf.


The Phase III KEYNOTE-024 trial assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) high expressing NSCLC.

The primary endpoint was progression-free survival (PFS), which was in favour of pembrolizumab with a prolongation of median PFS from 6 months to 10.3 months. There was also an improvement in overall survival (OS) as well as an improvement in response. Further, the tolerability was in favor of pembrolizumab.

We talked Dr Martin Reck about the trial. He explains that “this data will completely change our management of patients with advanced lung cancer”. In light of these findings, it is important to screen patients for PD-L1 expression and for those patients with high PD-L1 expression, pembrolizumab will be an option for first-line therapy.

If you would like to discover how we can leverage our network of relationships and understanding of the oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.

17th November 2016



Company Details

Brandcast Health

+44 (0)20 7291 5070

Contact Website

16-17 Little Portland Street

Latest content on this profile

Day 2 Round-up from the Giant Health Event
Robin gives a quick overview of day 2 of the Giant Health Event.
Brandcast Health
Why patient education is important in oncology
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
Brandcast Health
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
Brandcast Health
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.
Brandcast Health
FALCON trial of fulvestrant for advanced breast cancer
The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer.
Brandcast Health
Overview of the GIANT Health Event
Shafi Ahmed, PhD, FRCS, Director of Virtual Medics and Medical and GIANT Event Co-chair, provides an overview of the GIANT Health Event.
Brandcast Health